FDA Expands Precision Oncology Approvals Across Hematologic and Solid Tumors : Oncol Times | May 2026

Introduction

Recent FDA approvals continue to accelerate the shift toward biomarker-driven and targeted cancer therapy across hematologic malignancies and solid tumors. Novel immunotherapies and molecularly targeted agents are increasingly improving outcomes in diseases previously associated with limited therapeutic options.

Problem Statement

Despite major advances in oncology, patients with relapsed multiple myeloma, BRAF V600E–mutated metastatic colorectal cancer and HER2-mutated non-small cell lung cancer continue to face poor long-term outcomes and therapeutic resistance. Expanding effective targeted treatment options remains a major unmet clinical need.

Summary

This FDA update highlights three important regulatory approvals that reinforce the growing role of precision oncology and immune-directed therapy. Teclistamab combined with daratumumab hyaluronidase demonstrated substantial progression-free and overall survival benefit in relapsed or refractory multiple myeloma, establishing an effective early-line bispecific antibody–based strategy. However, the therapy carries important immune-related toxicities including cytokine release syndrome and neurotoxicity, necessitating REMS-based monitoring. In metastatic colorectal cancer, encorafenib combined with cetuximab and fluorouracil-based chemotherapy received traditional approval for treatment-naïve BRAF V600E–mutated disease following strong survival improvements in the BREAKWATER trial. The findings further validate BRAF-targeted therapy as a frontline precision treatment strategy in this historically aggressive colorectal cancer subtype. Meanwhile, zongertinib received accelerated approval for HER2-mutated advanced non-small cell lung cancer after demonstrating high objective response rates and durable responses in previously untreated patients. Collectively, these approvals illustrate several important trends in modern oncology: earlier integration of targeted therapies, expansion of biomarker-defined treatment paradigms and increasing reliance on molecular profiling to guide therapeutic selection. The update also underscores the continuing balance between efficacy and toxicity management as increasingly potent immune and targeted agents move into earlier lines of treatment.